23rd May 2006 16:30
AstraZeneca PLC23 May 2006 Dealing by DirectorsCompanies Act 1985 Sections 324/329 We hereby inform you that, on 19 May 2006, David R Brennan, a Director ofAstraZeneca PLC, was granted an option under the AstraZeneca Share Option Planover the Company's USD0.25 Ordinary Shares as follows. Number of shares over which Exercise price per Period when exercisable Total number of sharesoption is granted share under option 22,910 2848p 19.5.09-18.5.16 See below The option will become exercisable on 19 May 2009 subject to certain performanceconditions. The conditions, which will not be subject to any retesting, arethat the earnings per share of the Company must increase by the increase in theUK Retail Prices Index plus 5% per annum on average over three years, and thatno significant unforeseen event has taken place which, in the reasonable opinionof the Remuneration Committee, has resulted in major reputational damage toAstraZeneca, and the circumstances of which are exceptional enough to justifythe option not vesting and becoming exercisable. Failure to satisfy either orboth of these conditions will result in the lapse of the option in its entirety. Mr Brennan has previously received grants of options over the Company's AmericanDepositary Shares (ADSs). One ADS equals one Ordinary Share. Following thegrant of options referred to above, David Brennan has options over 110,641Ordinary Shares and 440,643 ADSs. We also inform you that on 19 May 2006 David R Brennan, a Director ofAstraZeneca PLC, was granted an award under the terms of the AstraZenecaPerformance Share Plan over the Company's USD0.25 Ordinary Shares as follows. Target number of Award price per Normal vesting date Total interest in shares Percentage ofshares awarded share after this award shares in issue 19,092 2848p 19 May 2009 See below See below The AstraZeneca Performance Share Plan was approved by shareholders at theCompany's AGM in 2005. Awards made under the Plan may not generally vest beforethe third anniversary of the relevant date of grant nor unless the specifiedperformance target(s) have been met at the end of the three year period which,for this award, is 1 January 2006 to 31 December 2008. The performance target that applies to this award is the Company's TotalShareholder Return ("TSR") compared to the TSR of a selected peer group of 12other pharmaceutical companies. The actual number of shares to which aparticipant may become unconditionally entitled will depend on the extent towhich the performance target(s) have been met. A summary of the Plan, includinga more detailed explanation of the performance target(s), can be found in theAstraZeneca Annual Report and Form 20-F Information 2005 which is available onthe Company's website www.astrazeneca.com. Mr Brennan has interests in both the Company's Ordinary Shares and AmericanDepositary Shares (ADSs). One ADS equals one Ordinary Share. Following theaward of Ordinary Shares referred to above, Mr Brennan now has an interest in98,553 Ordinary Shares and 167,453 ADSs, which together represent approximately0.017% of the number of shares currently in issue. G H R MuskerCompany Secretary23 May 2006 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca